Literature DB >> 18202854

Induction of apoptosis in PA-1 ovarian cancer cells by vitamin K2 is associated with an increase in the level of TR3/Nur77 and its accumulation in mitochondria and nuclei.

Toshiko Sibayama-Imazu1, Yukari Fujisawa, Yutaka Masuda, Toshihiro Aiuchi, Shigeo Nakajo, Hiroyuki Itabe, Kazuyasu Nakaya.   

Abstract

PURPOSE: We examined the growth-inhibitory and apoptosis-inducing effects of vitamin K(2) (VK(2); menaquinone-4) on various lines of human ovarian cancer cells to study the mechanism of induction of apoptosis by VK(2).
METHODS: Cell proliferation was determined by XTT method, and apoptotic cells were detected by Hoechst staining. TR3, also known as Nur77 and NGFI-B, was detected by immunoblotting and immunofluorescence analysis. Role of TR3 on induction of apoptosis was examined by a siRNA experiment. RESULTS AND
CONCLUSIONS: We found that PA-1 cells were the most sensitive to VK(2) (IC(50) = 5.0 +/- 0.7 microM), while SK-OV-3 cells were resistant to VK(2). Immunoblotting and immunofluorescence analyses indicated that levels of TR3 were elevated in cell lysates 48 h after the start of treatment with 30 microM VK(2). In the VK(2)-treated cells, TR3 accumulated at significant levels in mitochondria, as well as in the nuclei of PA-1 cells. No similar changes were observed in SK-OV-3 cells under the same conditions. Treatment of PA-1 cells with small interfering RNA (siRNA) directed against TR3, and with cycloheximide or SP600125 (an inhibitor of c-jun N-terminal kinase; JNK), separately, inhibited the VK(2)-induced synthesis of TR3 and apoptosis. From these results, we can conclude that an increase in the synthesis of TR3 and the accumulation of TR3 in mitochondria and in nuclei might be involved in the induction of apoptosis by VK(2) and that the synthesis of TR3 might be regulated through a JNK signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18202854     DOI: 10.1007/s00432-007-0349-z

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  43 in total

1.  Vitamin K2 and its derivatives induce apoptosis in leukemia cells and enhance the effect of all-trans retinoic acid.

Authors:  M Yaguchi; K Miyazawa; T Katagiri; J Nishimaki; M Kizaki; K Tohyama; K Toyama
Journal:  Leukemia       Date:  1997-06       Impact factor: 11.528

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  JNK (c-Jun N-terminal kinase) and p38 activation in receptor-mediated and chemically-induced apoptosis of T-cells: differential requirements for caspase activation.

Authors:  M MacFarlane; G M Cohen; M Dickens
Journal:  Biochem J       Date:  2000-05-15       Impact factor: 3.857

4.  Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells.

Authors:  K Miyazawa; M Yaguchi; K Funato; A Gotoh; Y Kawanishi; Y Nishizawa; A Yuo; K Ohyashiki
Journal:  Leukemia       Date:  2001-07       Impact factor: 11.528

5.  Elucidation of molecular events mediating induction of apoptosis by synthetic retinoids using a CD437-resistant ovarian carcinoma cell line.

Authors:  William F Holmes; Dianne Robert Soprano; Kenneth J Soprano
Journal:  J Biol Chem       Date:  2002-09-16       Impact factor: 5.157

6.  Early events in the induction of apoptosis in ovarian carcinoma cells by CD437: activation of the p38 MAP kinase signal pathway.

Authors:  William F Holmes; Dianne Robert Soprano; Kenneth J Soprano
Journal:  Oncogene       Date:  2003-09-25       Impact factor: 9.867

7.  Apoptosis induction of vitamin K2 in lung carcinoma cell lines: the possibility of vitamin K2 therapy for lung cancer.

Authors:  Tsuyoshi Yoshida; Keisuke Miyazawa; Ikuma Kasuga; Tomohisa Yokoyama; Kazushige Minemura; Kenta Ustumi; Masahiro Aoshima; Kazuma Ohyashiki
Journal:  Int J Oncol       Date:  2003-09       Impact factor: 5.650

8.  A human early response gene homologous to murine nur77 and rat NGFI-B, and related to the nuclear receptor superfamily.

Authors:  A Nakai; S Kartha; A Sakurai; F G Toback; L J DeGroot
Journal:  Mol Endocrinol       Date:  1990-10

9.  Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3.

Authors:  Bingzhen Lin; Siva Kumar Kolluri; Feng Lin; Wen Liu; Young-Hoon Han; Xihua Cao; Marcia I Dawson; John C Reed; Xiao-kun Zhang
Journal:  Cell       Date:  2004-02-20       Impact factor: 41.582

10.  Structure, mapping and expression of a growth factor inducible gene encoding a putative nuclear hormonal binding receptor.

Authors:  R P Ryseck; H Macdonald-Bravo; M G Mattéi; S Ruppert; R Bravo
Journal:  EMBO J       Date:  1989-11       Impact factor: 11.598

View more
  15 in total

1.  Metabolomics identifies the intersection of phosphoethanolamine with menaquinone-triggered apoptosis in an in vitro model of leukemia.

Authors:  Suganthagunthalam Dhakshinamoorthy; Nha-Truc Dinh; Jeffrey Skolnick; Mark P Styczynski
Journal:  Mol Biosyst       Date:  2015-09

2.  Induction of apoptosis in hepatocellular carcinoma Smmc-7721 cells by vitamin K(2) is associated with p53 and independent of the intrinsic apoptotic pathway.

Authors:  Lu Li; Zhiling Qi; Jin Qian; Fuyong Bi; Jun Lv; Lei Xu; Ling Zhang; Hongyu Chen; Renbing Jia
Journal:  Mol Cell Biochem       Date:  2010-05-07       Impact factor: 3.396

Review 3.  Molecular Pathways and Roles for Vitamin K2-7 as a Health-Beneficial Nutraceutical: Challenges and Opportunities.

Authors:  Nikita Jadhav; Saiprasad Ajgaonkar; Praful Saha; Pranay Gurav; Amitkumar Pandey; Vivek Basudkar; Yash Gada; Sangita Panda; Shashank Jadhav; Dilip Mehta; Sujit Nair
Journal:  Front Pharmacol       Date:  2022-06-14       Impact factor: 5.988

4.  HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML.

Authors:  L Zhou; V R Ruvolo; T McQueen; W Chen; I J Samudio; O Conneely; M Konopleva; M Andreeff
Journal:  Leukemia       Date:  2012-12-18       Impact factor: 11.528

5.  Orphan nuclear receptor Nur77 is required for the differentiation of C6 glioma cells induced by cholera toxin.

Authors:  Dong Xu; Yi-jun Huang; Yan Li; Wei Yin; Guang-mei Yan
Journal:  Acta Pharmacol Sin       Date:  2009-11       Impact factor: 6.150

6.  Modulation of orphan nuclear receptor Nur77-mediated apoptotic pathway by acetylshikonin and analogues.

Authors:  Jie Liu; Wen Zhou; Shao-Shun Li; Zhe Sun; Bingzhen Lin; Yuan-Yuan Lang; Jia-You He; Xihua Cao; Tingdong Yan; Li Wang; Jiongming Lu; Young-Hoon Han; Yu Cao; Xiao-kun Zhang; Jin-Zhang Zeng
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

7.  TR3 modulates platinum resistance in ovarian cancer.

Authors:  Andrew J Wilson; Annie Y Liu; Joseph Roland; Oluwafunmilayo B Adebayo; Sarah A Fletcher; James C Slaughter; Jeanette Saskowski; Marta A Crispens; Howard W Jones; Samuel James; Oluwole Fadare; Dineo Khabele
Journal:  Cancer Res       Date:  2013-05-29       Impact factor: 12.701

8.  Down-regulation of NR4A1 in follicular thyroid carcinomas is restored following lithium treatment.

Authors:  Cléber P Camacho; Flavia R M Latini; Gisele Oler; Flavio C Hojaij; Rui M B Maciel; Gregory J Riggins; Janete M Cerutti
Journal:  Clin Endocrinol (Oxf)       Date:  2008-08-22       Impact factor: 3.478

Review 9.  Vitamin K and its analogs: Potential avenues for prostate cancer management.

Authors:  Subramanyam Dasari; Syed M Ali; Guoxing Zheng; Aoshuang Chen; Venkata Satish Dontaraju; Maarten C Bosland; Andre Kajdacsy-Balla; Gnanasekar Munirathinam
Journal:  Oncotarget       Date:  2017-05-19

10.  Vitamin k2, a naturally occurring menaquinone, exerts therapeutic effects on both hormone-dependent and hormone-independent prostate cancer cells.

Authors:  Abhilash Samykutty; Aditya V Shetty; Gajalakshmi Dakshinamoorthy; Ramaswamy Kalyanasundaram; Gouxing Zheng; Aoshuang Chen; Maarten C Bosland; André Kajdacsy-Balla; Munirathinam Gnanasekar
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-24       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.